Anlon Healthcare’s shares debuted with a modest 1% premium amid volatile pharma markets, despite a strong 7.12x IPO subscription driven by retail investors. The specialized API manufacturer showed robust financial growth, with revenue up 81% in FY25 and expanding profit margins. While niche products and global approvals boost prospects, risks include limited operating history and regulatory challenges. Analysts consider the IPO fully priced.
Anlon Healthcare shares make a tepid debut. Should IPO investors wait or sell?
September 3, 2025
Recent Post
ARC Insulation IPO allotment date likely today. GMP, steps to check share allotment status online
August 26, 2025
Stock market holiday: Is the Indian stock market open or closed on Ganesh Chaturthi 2025?
August 26, 2025
Japan’s Nikkei ends at over 2-week low as yen gains after Trump fires Fed’s Cook
August 26, 2025
Have Any Question?
Do not hesitate to contact us. We’re a team of experts ready to talk to you.
